<DOC>
	<DOCNO>NCT01037621</DOCNO>
	<brief_summary>This trial determine safety valacyclovir person chronic hepatitis C herpes simplex type 2 infection . Participants randomize valacyclovir match placebo . After receive initial therapy eight week , participant cross alternate therapy additional eight week . Each treatment period separate two-week period daily placebo . The hypothesis treatment valacyclovir result significant reduction serum level hepatitis C virus ribonucleic acid .</brief_summary>
	<brief_title>Herpes Simplex Type 2 Co-infection Veterans With Chronic Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Herpes Simplex</mesh_term>
	<mesh_term>Coinfection</mesh_term>
	<mesh_term>Valacyclovir</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<criteria>Clinical diagnosis hepatitis C infection Clinical diagnosis herpes simplex type 2 infection HIV infection Other form chronic liver disease Chronic medical condition On immunosuppressive medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Herpes simplex type 2</keyword>
	<keyword>Hepatitis C virus</keyword>
	<keyword>Valacyclovir</keyword>
	<keyword>Herpes Simplex virus type 2 infection</keyword>
</DOC>